Morningstar

Chugai Pharmaceutical Co Ltd 4519

Morningstar Rating
Unlock
Stock XTKS Rating as of
¥‎6,980.00 +129.00 (1.88%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Price vs Fair Value

View History
4519 is trading at a 270% premium.
Price
¥‎6,851.00
Fair Value
¥‎3,346.00
Uncertainty
High
1-Star Price
¥‎3,325.00
5-Star Price
¥‎5,974.00
Economic Moat
Lzxxfb
Capital Allocation
Zldgskt

Bulls Say, Bears Say

Bulls

Chugai is developing cutting-edge antibody technologies and midsize molecules that have the potential to change treatment paradigms that older modalities cannot address.

Bears

Despite its early success, Hemlibra could see challenges from longer-acting competitors within a few years.

Show More

Trading Information

Previous Close Price
¥‎6,851.00
Day Range
¥‎6,932.00–7,078.00
52-Week Range
¥‎4,234.00–7,485.00
Bid/Ask
¥‎6,979.00 / ¥‎6,999.00
Market Cap
¥‎11.49 Tril
Volume/Avg
1.6 Mil / 2.6 Mil

Key Statistics

Price/Earnings (Normalized)
33.00
Price/Sales
10.39
Dividend Yield (Trailing)
1.18%
Dividend Yield (Forward)
1.20%
Total Yield
1.18%

Company Profile

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
7,604
Website
http://www.chugai-pharm.co.jp

Competitors

Valuation

View More
Metric
4519
4502
4568
Price/Earnings (Normalized)
 33.0015.6845.51
Price/Book Value
 6.440.835.28
Price/Sales
 10.391.495.28
Price/Cash Flow
 28.697.4433.26
Price/Earnings
4519
4502
4568

Financial Strength

Metric
4519
4502
4568
Quick Ratio
 4.020.662.32
Current Ratio
 5.091.263.01
Interest Coverage
 —1.2135.14
Quick Ratio
4519
4502
4568

Profitability

Metric
4519
4502
4568
Return on Assets (Normalized)
 18.61%2.91%6.99%
Return on Equity (Normalized)
 22.00%6.11%12.93%
Return on Invested Capital (Normalized)
 21.98%4.29%10.69%
Return on Assets
4519
4502
4568

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
HmfzcqhxZpxr$802.3 Bil
 Johnson & Johnson
JNJ
JrpxbmqgTdzj$388.0 Bil
 AbbVie Inc
ABBV
KsnfsrfrMgrg$347.7 Bil
 Merck & Co Inc
MRK
NxbmxnrXcpyj$284.1 Bil
 Roche Holding AG ADR
RHHBY
PqkfzlzxhCymm$252.2 Bil
 AstraZeneca PLC ADR
AZN
FpqkqywbnbCwxc$245.8 Bil
 Novartis AG ADR
NVS
XkvrkkwknQyl$232.6 Bil
 Amgen Inc
AMGN
WvbrnpdktHtmc$171.8 Bil
 Pfizer Inc
PFE
SzwqzvsNyjjt$162.1 Bil
 Sanofi SA ADR
SNY
VbdfpnsdVxxx$141.7 Bil

Sponsor Center